In a report released on March 28, Francois Brisebois from Oppenheimer maintained a Buy rating on Sensei Biotherapeutics (SNSE – Research ...

H.C. Wainwright lowered the firm’s price target on Co-Diagnostics (CODX) to $1 from $1.50 and keeps a Neutral rating on the shares following ...

H.C. Wainwright keeps a Buy rating on Milestone Pharmaceuticals (MIST) after the company announced receipt of a complete response letter from ...

H.C. Wainwright analyst Joseph Pantginis raised the firm’s price target on Aptose Biosciences (APTO) to $6 from $2 and keeps a Buy rating on ...

H.C. Wainwright analyst Edward White reiterated a Hold rating on Inhibikase Therapeutics (IKT – Research Report) today. The company’s shares ...

H.C. Wainwright lowered the firm’s price target on Acumen (ABOS) to $11 from $15 and keeps a Buy rating on the shares. The firm says completion ...

H.C. Wainwright lowered the firm’s price target on Plus Therapeutics (PSTV) to $5.50 from $8 and keeps a Buy rating on the shares. The firm ...

H.C. Wainwright analyst Joseph Pantginis lowered the firm’s price target on Tempest Therapeutics (TPST) to $16 from $47 and keeps a Buy rating ...

H.C. Wainwright raised the firm’s price target on Americas Gold and Silver (USAS) to $1 from 90c and keeps a Buy rating on the shares following ...

H.C. Wainwright raised the firm’s price target on Worksport (WKSP) to $11.50 from $1.50 and keeps a Buy rating on the shares following this ...

H.C. Wainwright lowered the firm’s price target on Bitfarms (BITF) to $3.50 from $4 and keeps a Buy rating on the shares. The firm also added ...

H.C. Wainwright analyst Ed Arce maintained a Hold rating on Durect (DRRX – Research Report) today. The company’s shares opened today at ...